Pharma Update
Holistic, end-to-end analysis of our R&D productivity
Commitment to delivering the worlds most impactful medicines
•
Success rate ✓ Volume
✓
Value
Effectiveness
R&D productivity
=
Costs
Cycle time
}
Efficiency
Holistic and end-to-end
Teams from early to late stage
development, and commercial involved
'Leave no stone unturned' analysis
RWD-real-world data; AI/ML-artificial intelligence/machine learning
☐ Strong base
Ability to capitalize on significant past
investments, for example:
.
Breadth of disease area talent
.
Computational biology expertise
Platform technologies
☑» New opportunities
RWD and Al/ML, computational biology
and advanced analytics
.
Application of new technologies in R&D
Institute of Human Biology (IHB)
Roche
22View entire presentation